Les Newsletters de Stop-Tabac.ch

Webmasters - Proposez nos news sur votre site

Rechercher dans les anciennes newsletter:

26 août 2014

La newsletter de stop-tabac: les sujets clés de l?actualité mondiale sur le tabagisme

Sélection réalisée par Jean-François Etter

Le 26 aout 2014


- Philipp Morris a baptisé sa cigarette chauffante IQOS
- Selon l'OMS, l'alcool tue une personne toutes les 10 secondes
- Evaluation of a Novel Nicotine Inhaler Device. Part 2: Effect on Craving and Smoking Urges
- Chattez avec un médecin tabacologue


Philipp Morris a baptisé sa cigarette chauffante IQOS

Ce sera iQos. C'est ainsi que Philip Morris a décidé de baptiser son nouveau-né. Après une décennie et plusieurs milliards de dollars de recherches et de tests, essentiellement réalisés sur son site de Neuchâtel (LT du 14.02.2014), la multinationale est prête à lancer son nouveau dispositif électrique. Le principe? Le consommateur insère un stick une sorte de cigarette raccourcie dans un étui qui chauffe le tabac au lieu de le brûler, évitant la combustion et réduisant les inhalations de constituants nocifs. Lire la suite;...

http://www.letemps.ch/Page/Uuid/ee4dabd4-fe28-11e3-b606-e345e71cec86/Philipp_Morris_a_baptis%C3%A9_sa_cigarette_chauffante (22 07 2014)
(26 08 2014)


Selon l'OMS, l'alcool tue une personne toutes les 10 secondes

L'Organisation mondiale de la santé s'inquiète de la hausse de la consommation d'alcool dans le monde et des 3,3 millions de morts qu'elle provoque chaque année. Eclairage sur ces chiffres inquiétants:

http://www.lemonde.fr/sante/video/2014/08/08/selon-l-oms-l-alcool-tue-une-personne-toutes-les-10-secondes_4469396_1651302.html#xtor=AL-32280270 (13 08 2014)
(26 08 2014)


Evaluation of a Novel Nicotine Inhaler Device. Part 2: Effect on Craving and Smoking Urges

Introduction: Many smokers find currently available nicotine replacement therapies unsatisfactory. The pharmacokinetics of nicotine delivered via a novel inhaler device, and its effect on craving satiation and smoking urges, were compared with the Nicorette Inhalator (10mg).

Methods: Results are reported for Parts B (N = 24) and D (N = 24) of a 4-part Phase I study. Participants (1855 years, ?10 cigarettes/day within 1hr of waking, expired carbon monoxide >10 ppm on screening) received single doses of nicotine on consecutive days (0.45 and 0.67mg [Part B] and 0.45mg [Part D] via the novel device; 10mg via Nicorette [Parts B and D]). Venous pharmacokinetics, craving, and tolerability were assessed.

Results: In Part B, the novel device 0.45 and 0.67mg produced significantly lower C max, AUClast, and AUCall than Nicorette (all p ? .05), higher AUC010 and significantly shorter T max (18.7 and 19.2min vs. 38.0min, respectively, p ? .05). Craving score AUC was lower for the novel device 0.45mg than for Nicorette in Part B (1356.3 vs. 1566.3, p = .029) and approached statistical significance in Part D (1208.5 vs. 1402.3 [p = .059]). Mean craving scores were lower for the novel device 0.45mg than Nicorette at 7/8 postdose timepoints in Part B (p ? .05 at 180 and 240min) and at all timepoints in Part D (p ? .05 at 2, 4, and 10min).

Conclusions: The novel device was at least as effective as the Nicorette Inhalator (10mg) in relieving craving and smoking urges and was statistically superior at certain timepoints and in an overall craving AUC analysis, despite lower total nicotine exposure.

Chris Moyses, MRCP, DM1, Alex Hearn, MA1 and Andrew Redfern, MRCP, FRACP2 - Nicotine & Tobacco Research - July 2014

http://ntr.oxfordjournals.org/content/early/2014/07/30/ntr.ntu122.abstract (06 08 2014)
(26 08 2014)



Retour à la liste des newsletters